Mridula George, MD, discusses efforts to address unmet needs in HER2-low breast cancer.

Mridula George, MD, medical oncologist, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, assistant professor of medicine, Rutgers Robert Wood Johnson Medical School, discusses efforts to address unmet needs in HER2-low breast cancer.

The phase 3 DESTINY-Breast04 trial (NCT03734029) investigated fam-trastuzumab deruxtecan-nxki (Enhertu) vs. physicians choice of chemotherapy in patients with unresectable or metastatic HER2-low breast cancer. This study was pivotal because there is currently no treatment for this subgroup of patients, George says.

DESTINY-Breast04 met its primary end point of progression free survival, plus the secondary end point of overall survival in the subgroup of patients with hormone receptorpositive disease, George explains.

Future research could explore potential combinations withtrastuzumab deruxtecan, such as CDK4/6 inhibitors, George continues. The HER2-low space will generate more clinical trials to better understand treatment options for this subtype of breast cancer, George concludes.

Here is the original post:
Dr. George on Efforts to Address Unmet Needs in HER2-Low Breast Cancer - OncLive

Comments are closed.